Timothy Barberich has nearly 40 years’ experience in pharmaceutical and medical device companies, in technical, sales, marketing and management positions, including chief executive officer and chairman of the board. Mr. Barberich is founder and former Chairman and CEO of Sepracor Inc., a research-based pharmaceutical company which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009, now known as Sunovion Pharmaceuticals.
Mr. Barberich served as CEO of Sepracor from 1984 to 2007 and as Chairman of the Board from 1990 to 2009. Mr. Barberich currently serves on the board of directors of publicly-traded, Verastem Inc. [NASDAQ: VSTM], and on the boards of the privately held companies including TScan Therapeutics and Frequency Therapeutics. He has previously served on the boards of several public and private biotech and medical device companies. Mr. Barberich has also served on the board of trustees of Boston Medical Center and as a member of the board of the Pharmaceutical Research and Manufacturers’ Association (PhRMA). Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation.